[go: up one dir, main page]

DK3335729T3 - Etanercept-sammensætning med forbedret stabilitet - Google Patents

Etanercept-sammensætning med forbedret stabilitet Download PDF

Info

Publication number
DK3335729T3
DK3335729T3 DK16835520.4T DK16835520T DK3335729T3 DK 3335729 T3 DK3335729 T3 DK 3335729T3 DK 16835520 T DK16835520 T DK 16835520T DK 3335729 T3 DK3335729 T3 DK 3335729T3
Authority
DK
Denmark
Prior art keywords
improved stability
etanercept formulation
etanercept
formulation
stability
Prior art date
Application number
DK16835520.4T
Other languages
Danish (da)
English (en)
Inventor
Breña Romero De Terreros Francisco Kuri
Original Assignee
Landsteiner Scient S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57983405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3335729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Landsteiner Scient S A De C V filed Critical Landsteiner Scient S A De C V
Application granted granted Critical
Publication of DK3335729T3 publication Critical patent/DK3335729T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16835520.4T 2015-08-13 2016-08-09 Etanercept-sammensætning med forbedret stabilitet DK3335729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2015010517A MX389818B (es) 2015-08-13 2015-08-13 Composicion de estabilidad mejorada de etanercept.
PCT/MX2016/000082 WO2017026881A1 (es) 2015-08-13 2016-08-09 Composición de estabilidad mejorada de etanercept

Publications (1)

Publication Number Publication Date
DK3335729T3 true DK3335729T3 (da) 2023-07-10

Family

ID=57983405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16835520.4T DK3335729T3 (da) 2015-08-13 2016-08-09 Etanercept-sammensætning med forbedret stabilitet

Country Status (9)

Country Link
EP (1) EP3335729B1 (es)
JP (1) JP6852049B2 (es)
BR (1) BR112018002970A2 (es)
CO (1) CO2018002575A2 (es)
DK (1) DK3335729T3 (es)
ES (1) ES2956008T3 (es)
MX (1) MX389818B (es)
PT (1) PT3335729T (es)
WO (1) WO2017026881A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478394T3 (da) * 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9302002B2 (en) * 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
CA2878508A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PL2919801T3 (pl) * 2012-10-26 2021-01-25 Lupin Atlantis Holdings, Sa Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu

Also Published As

Publication number Publication date
PT3335729T (pt) 2023-09-26
JP6852049B2 (ja) 2021-03-31
MX2015010517A (es) 2017-02-13
BR112018002970A2 (pt) 2019-03-19
ES2956008T3 (es) 2023-12-11
EP3335729A4 (en) 2019-06-05
WO2017026881A1 (es) 2017-02-16
MX389818B (es) 2025-03-20
EP3335729B1 (en) 2023-06-28
CO2018002575A2 (es) 2018-06-12
EP3335729A1 (en) 2018-06-20
JP2018527343A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
EP3337502A4 (en) STABLE ANTI-IFNAR1 FORMULATION
EP3493800A4 (en) CANNABIS
DK3040326T3 (da) Haloolefin-baseret sammensætning
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
KR102494289B9 (ko) 활성 혼합물
FR3024363B1 (fr) Composition thermogelifiable
DK3310340T3 (da) Formulering med høj koncentration
CL2015001019S1 (es) Ampolleta
DK3528902T3 (da) Ringegelsammensætning
HUE054245T2 (hu) Immunszupresszáns formuláció
EP3560512A4 (en) COMPOSITION OF VACCINE AGAINST ZONA
DK3212237T3 (da) Methotrexatformulering
PL3207149T3 (pl) Kompozycja farmaceutyczna o zwiększonej stabilności
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
CL2017000639A1 (es) Composición
EP3480228A4 (en) COMPOSITION
DK3322295T3 (da) Sammensætning
DK3337353T3 (da) Stol
DK3331498T3 (da) Nasalsammensætning
SI3173071T1 (sl) Formulacija maropitanta
DK3393254T3 (da) Sammensætning
EP3369418A4 (en) COMPOSITION
HUE070090T2 (hu) Összetétel
EP3443034C0 (en) COMPOSITION